Seres Therapeutics Reports Third Quarter 2016 Financial Results And Provides Operational Progress Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform Company, today reported third quarter 2016 financial results and provided an update on multiple clinical programs, including three clinical-stage candidates seeking to address multiple medical indications.
“Our focus has been on completing data analyses related to the previously reported SER-109 Phase 2 study results in patients with multiply recurrent C. difficile infection,” said Roger Pomerantz, M.D., President, CEO and Chairman of Seres, “We expect to complete these efforts by year end and subsequently plan to meet with the FDA to discuss our findings and proposed plans for further SER-109 clinical development.”
“Our focus has been on completing data analyses related to the previously reported SER-109 Phase 2 study results in patients with multiply recurrent C. difficile infection,” said Roger Pomerantz, M.D., President, CEO and Chairman of Seres, “We expect to complete these efforts by year end and subsequently plan to meet with the FDA to discuss our findings and proposed plans for further SER-109 clinical development.”